Everolimus is an immunosuppressant that was approved for its medical use on 30th March 2009.

Everolimus has been developed to treat advanced hormone receptor-positive breast cancer, pancreatic cancer (pancreatic neuroendocrine tumour), and neuroendocrine tumour of the stomach, lung, and intestine that cannot be treated with surgery.

Take the Everolimus Tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The common side effects that are likely to occur while you are on the treatment with everolimus are fever, chills, skin rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing. If you experience any allergic reactions such as rashes, itching, hive, flushing, chest pain, dizziness, trouble breathing, or swallowing. report to your doctor immediately.

Contact your doctor immediately if you experience shortness of breath, chest pain, or worsening cough. During the everolimus treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Report to your doctor if you have been diagnosed with liver disorders, kidney problems, heart failure, high blood cholesterol levels, or hypertension before starting this treatment.

Everolimus tablets have the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. This medicine passes into breast milk. Hence, it is not recommended to breastfeed during this treatment.

Avoid driving or operating heavy machinery if you experience dizziness or any discomfort during treatment with Everolimus Tablet. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. 

1. Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf 
2. Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
3. Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
4. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
5. KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.